Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment

Journal of Clinical Rheumatology

Volumn 17, Issue 7, 2011, Pages 358-362

  Bilgen, Sule Apras ^a   Kilic, Levent ^a   Akdogan, Ali ^a   Kiraz, Sedat ^a   Kalyoncu, Umut ^a   Karadag, Omer ^a   Ertenli, Ihsan ^a   Dogan, Ismail ^a   Calguneri, Meral ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

amyloidosis; anti tumor necrosis factor agents; chronic arthritis; familial Mediterranean fever; spondyloarthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; COLCHICINE; CREATININE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; AMYLOIDOSIS; ARTHRITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CHRONIC ARTHRITIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SACROILIAC JOINT; SACROILIITIS; SCORING SYSTEM; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE-PHASE PROTEINS; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLCHICINE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GOUT SUPPRESSANTS; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SACROILIITIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80053369942     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823682f5     Document Type: Review

References (37)

1. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473-483.
2. Rabinovich E, Livneh A, Langevitz P, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis. 2005;64:1009-1014.
3. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis. 2000;59:428-433.
4. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46:755-765.
5. Nakamura A, Matsuda M, Tazawa K, et al. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med. 2007;46:1247-1249.
6. Ozgocmen S, Ozcakar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: Single case experience. Clin Rheumatol. 2006;25:83-87.
7. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879-1885.
8. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: Clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273-282.
9. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
10. Uthman I, Hajj-Ali RA, Arayssi T, et al. Arthritis in familial Mediterranean fever. Rheumatol Int. 2001;20:145-148.
11. Lidar M, Kedem R, Mor A, et al. Arthritis as the sole episodic manifestation of familial Mediterranean fever. J Rheumatol. 2005;32:859-862.
12. Kasifoglu T, Calisir C, Cansu DU, et al. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol. 2009;28:41-46.
13. Drenth JP, van Deuren M, van derVen-Jongekrijg J, et al. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood. 1995;85:3586-3593.
14. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544-1549.
15. Baykal Y, Saglam K, Yilmaz MI, et al. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol. 2003;22:99-101.
16. Kiraz S, Ertenli I, Arici M, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol. 1998;16:721-724.
17. Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: Reportof three cases and review of the literature [published online ahead of print May 13, 2011]. Mod Rheumatol. 2011.
18. Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: Anti-TNF drugs and FMF [published online ahead of print]. Rheumatol Int. 2011.
19. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659-664.
20. Tweezer-Zaks N, Rabinovich E, Lidar M, et al. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol. 2008;35:1362-1365.
21. Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38:516-518.
22. Chae JJ, Komarow HD, Cheng J, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell. 2003;11:591-604.
23. Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24:S99YS103.
24. Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: Report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997;156:619-623.
25. Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: Correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5:4.
26. Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: Report of three Turkish cases. Rheumatol Int. 2006;27:197-199.
27. Vandecasteele SJ, De Paepe P, De Vriese AS. Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. Clin Nephrol. 2011;75(suppl 1):1-3.
28. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349-2360.
29. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis Rheum. 2003;48:2019-2024.
30. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118:552-556.
31. Metyas S, Arkfeld DG, Forrester DM, et al. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10:134-137.
32. Yuksel S, Yalcinkaya F, Acar B, et al. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2006;45:1307-1308.
33. Bodur H, Seckin U, Eser F, et al. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Int. 2008;29:107-110.
34. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64-69.
35. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6:643-651.
36. Tanaka N, Yonekura H, Yamagishi S, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000;275:25781-25790.
37. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptorYassociated periodic syndrome. N Engl J Med. 2000 343 1044-1045.